Who
James S. J. Manuso
Director
Company insider
Files Form 4 as: Director, Opus Genetics; Director, TuHURA Biosciences; President and CEO, RespireRx Pharmaceuticals; Chief Executive Officer, Astex Pharmaceuticals.
In numbers
- Trades disclosed
- 98
- Buys
- 6
- Sells
- 3
- Bought
- $22K
- Sold
- $571K
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 3 Jan 2006
- Last trade
- 20 Apr 2026
- Last filed
- 22 Apr 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 20 Apr 2026filed 22 Apr 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code A | —24,367 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code A | —24,367 at $0.00 | filing |
| 12 Feb 2026filed 17 Feb 2026 | HURA TuHURA Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —156,240 at $0.00 | filing |
| 12 Feb 2026filed 17 Feb 2026 | HURA TuHURA Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —156,240 at $0.00 | filing |
| 1 Jan 2026filed 5 Jan 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code A | —31,188 | filing |
| 1 Jan 2026filed 5 Jan 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code A | —31,188 | filing |
| 30 Apr 2025filed 2 May 2025 | IRD Opus Geneticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —79,592 at $0.00 | filing |
| 30 Apr 2025filed 2 May 2025 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code A | —79,504 at $0.00 | filing |
| 2 Jan 2025filed 6 Jan 2025 | HURA TuHURA Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —59,590 at $0.00 | filing |
| 2 Jan 2025filed 6 Jan 2025 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code A | —50,222 | filing |
| 18 Oct 2024filed 22 Oct 2024 | HURA TuHURA Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,553 at $0.00 | filing |
| 18 Oct 2024filed 22 Oct 2024 | HURA TuHURA Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,553 at $0.00 | filing |
| 11 Jun 2024filed 13 Jun 2024 | IRD Opus Geneticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,181 at $0.00 | filing |
| 11 Jun 2024filed 13 Jun 2024 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code A | —41,143 at $0.00 | filing |
| 1 Jan 2024filed 3 Jan 2024 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code A | —22,090 | filing |
| 6 Jun 2023filed 8 Jun 2023 | IRD Opus Geneticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,639 at $0.00 | filing |
| 6 Jun 2023filed 8 Jun 2023 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code A | —10,976 at $0.00 | filing |
| 19 Apr 2023filed 21 Apr 2023 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code A | —2,819 | filing |
| 11 Jan 2023filed 12 Jan 2023 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code A | —18,544 | filing |
| 11 Oct 2022filed 12 Oct 2022 | IRD Opus Geneticsoption or derivative · Biotechnology | SEC FORM 4 Code X | —787 at $0.00 | filing |
News
Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of PresbyopiaIRD · manilatimes.net · 16 Oct 2026Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026IRD · manilatimes.net · 15 Oct 2026Opus Genetics to Present at the Chardan Annual Healthcare ConferenceIRD · manilatimes.net · 13 Oct 2026
0 headlines in the last 90 days name James S. J. Manuso; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.